MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers..

MAIA生物技术公司（纽约证券交易所代码：MAIA），一家专注于开发癌症靶向免疫疗法的临床阶段生物医药公司，今日宣布与罗氏达成了一项临床主供应协议，用于未来研究MAIA的端粒靶向药物替拉诺苷（THIO）与罗氏的检查点抑制剂（CPI）阿特珠单抗（Tecentriq®）联用在治疗多种难治性癌症中的效果。

“In preclinical studies, ateganosine was found to be highly synergistic and effective in combination with Roche’s anti-PD-L1 agent atezolizumab,” said MAIA Chairman and CEO Vlad Vitoc, M.D. “We are pleased to partner with world-renowned Roche and we look forward to further strengthening our mission to find safe and effective cancer treatments.”.

“在临床前研究中，发现ateganosine与罗氏的抗PD-L1药物atezolizumab联合使用时具有高度协同性和有效性，”MAIA董事长兼首席执行官Vlad Vitoc博士表示，“我们很高兴能与世界知名的罗氏合作，并期待进一步推进我们寻找安全有效的癌症治疗方法的使命。”

About Ateganosine

关于Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.

Ateganosine（THIO、6-thio-dG 或 6-thio-2'-脱氧鸟苷）是一种首创的端粒靶向药物，目前正处于临床开发阶段，以评估其在非小细胞肺癌（NSCLC）中的活性。端粒以及端粒酶在癌细胞的存活及其对当前疗法的耐药性中发挥着关键作用。

The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activate both innate (cGAS/STING) and adaptive (T-cell) immune responses.

修饰核苷酸6-硫代-2'-脱氧鸟苷诱导端粒酶依赖性的端粒DNA修饰、DNA损伤反应和选择性癌细胞死亡。Ateganosine损伤的端粒片段在胞质微核中积累，并激活先天（cGAS/STING）和适应性（T细胞）免疫反应。

The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors..

顺序使用ateganosine治疗后，再使用PD-(L)1抑制剂，在晚期体内癌症模型中，通过诱导特定癌症类型的免疫记忆，导致了显著且持久的肿瘤消退。Ateganosine目前正被开发作为二线或更晚线的治疗方案，用于那些已经超出标准治疗方案（现有的检查点抑制剂）的非小细胞肺癌（NSCLC）患者。

About MAIA Biotechnology, Inc.

关于MAIA生物技术公司

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

MAIA 是一家专注于靶向治疗和免疫肿瘤学的公司，致力于开发和商业化具有新颖作用机制的潜在首创药物，旨在有意义地改善和延长癌症患者的生命。我们的主要项目是 Ateganosine（THIO），这是一种潜在的首创癌症端粒靶向剂，目前正处于临床开发阶段，用于治疗端粒酶阳性的非小细胞肺癌（NSCLC）患者。